• Call us now: 0300 303 0444
  • Call us now: 0300 303 0444
News

You are here

Zika virus vaccine update

19 May, 2017

Zika virus vaccine update

A research paper has been published on the three potential Zika virus vaccines that are being tested in humans at present. 

Two are based on cutting-edge DNA vaccine technology and the third is based on the more standard inactivated virus model.

The DNA vaccines under development interfere with the virus' ability to enter cells and replicate itself, while the inactivated vaccine aims to create an immune response that would provide future protection against Zika.

Of the three, a DNA vaccine developed by the US National Institutes of Health has progressed the furthest, with a large multi-site phase 2 trial underway involving almost 2500 test subject.

Stephen Thomas, one of the authors of the paper, said research and development has been ‘incredibly brisk’ and that ‘some groundbreaking strides have been made in very short periods of time’.

The paper states: ‘The development of a safe and effective vaccine is an urgent global health priority. 

‘Promising data from preclinical vaccine studies in mice and monkeys suggest that an effective vaccine will likely be possible, but important scientific challenges remain.’

The research has been published in the journal Immunity, to read the abstract, click here.

Printer-friendly version